Antibody-independent surface plasmon resonance assays for influenza vaccine quality control
Applied Microbiology and Biotechnology · 2024
DOI: 10.1007/s00253-024-13145-y ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Applied Microbiology and Biotechnology, 2024. Verfasst von Benjamin Serafin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical Engineering, Polytechnique Montreal, Montreal, QC, Canada. Hauptthemen laut MEDLINE: Surface Plasmon Resonance, Influenza Vaccines, Quality Control. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fonds de recherche du Québec - Nature et technologies, Fonds de recherche du Québec – Nature et technologies.
Abstract (Originalsprache)
Surface plasmon resonance (SPR)-based biosensors have emerged as a powerful platform for bioprocess monitoring due to their ability to detect biointeractions in real time, without the need for labeling. Paramount for the development of a robust detection platform is the immobilization of a ligand with high specificity and affinity for the in-solution species of interest. Following the 2009 H1N1 pandemic, much effort has been made toward the development of quality control platforms for influenza A vaccine productions, many of which have employed SPR for detection. Due to the rapid antigenic drift of influenza’s principal surface protein, hemagglutinin, antibodies used for immunoassays need to be produced seasonally. The production of these antibodies represents a 6–8-week delay in immunoassay and, thus, vaccine availability. This review focuses on SPR-based assays that do not rely on anti-HA antibodies for the detection, characterization, and quantification of influenza A in bioproductions and biological samples. Key points • The single radial immunodiffusion assay (SRID) has been the gold standard for the quantification of influenza vaccines since 1979. Due to antigenic drift of influenza’s hemagglutinin protein, new antibody reagents for the SRID assay must be produced each year, requiring 6–8 weeks. The resulting delay in immunoassay availability is a major bottleneck in the influenza vaccine pipeline. This review highlights ligand options for the detection and quantification of influenza viruses using surface plasmon resonance biosensors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemical Engineering, Polytechnique Montreal, Montreal, QC, Canada.
- Department of Bioengineering, McGill University, Montreal, QC, Canada.
- Department of Chemical Engineering, Polytechnique Montreal, Montreal, QC, Canada. olivier.henry@polymtl.ca.
Förderung
- Fonds de recherche du Québec - Nature et technologies
- Fonds de recherche du Québec – Nature et technologies
Zitieren
APA
Serafin, B., Kamen, A., de Crescenzo, G., & Henry, O. (2024). Antibody-independent surface plasmon resonance assays for influenza vaccine quality control. Applied Microbiology and Biotechnology. https://doi.org/10.1007/s00253-024-13145-y
Vancouver
Serafin B, Kamen A, de Crescenzo G, Henry O. Antibody-independent surface plasmon resonance assays for influenza vaccine quality control. Applied Microbiology and Biotechnology. 2024. doi:10.1007/s00253-024-13145-y
BibTeX
@article{Serafin2024,
author = {Serafin, Benjamin and Kamen, Amine and de Crescenzo, Gregory and Henry, Olivier},
title = {Antibody-independent surface plasmon resonance assays for influenza vaccine quality control},
journal = {Applied Microbiology and Biotechnology},
year = {2024},
doi = {10.1007/s00253-024-13145-y}
}
EUVIMED